How can we improve the quality of reporting family history in colorectal cancer care? (And why does it matter?)

By Wilson Brenda J  

Colorectal Cancer, Vol. 2, Iss. 2, 2013-04 ,pp. : 99-102

Future Medicine

Access to resources Recommend Favorite

Ductal carcinoma in situ: how should we treat it?

By Bayraktar Soley   Arun Banu   Glück Stefan  

Breast Cancer Management, Vol. 2, Iss. 3, 2013-05 ,pp. : 245-256

Future Medicine

Access to resources Recommend Favorite

Perioperative Chemotherapy for Gastric Cancer: How Should We Measure the Efficacy?

By Persiani Roberto  

Annals of Surgical Oncology, Vol. 16, Iss. 4, 2009-04 ,pp. : 1077-1079

Springer Publishing Company

Access to resources Recommend Favorite

How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?

By Lindsay Colin R   Roxburgh Patricia   Graham Janet  

Future Oncology, Vol. 9, Iss. 6, 2013-06 ,pp. : 825-829

Future Medicine

Access to resources Recommend Favorite

Hysteroscopic Assessment of Menopausal Breast-Cancer Patients Taking Tamoxifen; There is a Bias from the Mode of Endometrial Sampling in Estimating Endometrial Morbidity?

By Garuti Giancarlo   Grossi Francesco   Cellani Fulvia   Centinaio Giovanna   Colonnelli Monica   Luerti Massimo  

Breast Cancer Research and Treatment, Vol. 72, Iss. 3, 2002-04 ,pp. : 245-253

Springer Publishing Company

Access to resources Recommend Favorite